Pluri Inc. Form ARS: Annual report to security holders
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-04-23: Form ARS; Period of report 2025-06-30; Description FORM ARS; Document ea0286813-ars_pluri.pdf.
- 2025-05-27: Form ARS; Period of report 2024-12-31; Description ARS; Document ea023424004-ars_pluri.pdf.
- 2024-05-01: Form ARS; Period of report 2023-06-30; Description ARS; Document pluri_ars.pdf.
- 2023-02-27: Form ARS; Period of report 2022-06-30; Description FORM ARS; Document ea174283-ars_pluriinc.pdf.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-04-23 | ARS | 2025-06-30 | FORM ARS | ea0286813-ars_pluri.pdf |
| 2025-05-27 | ARS | 2024-12-31 | ARS | ea023424004-ars_pluri.pdf |
| 2024-05-01 | ARS | 2023-06-30 | ARS | pluri_ars.pdf |
| 2023-02-27 | ARS | 2022-06-30 | FORM ARS | ea174283-ars_pluriinc.pdf |
| 2015-04-13 | ARS | 2014-06-30 | AUTO-GENERATED PAPER DOCUMENT | 9999999997-15-008630.paper |
| 2011-04-25 | ARS | 2010-06-30 | AUTO-GENERATED PAPER DOCUMENT | 9999999997-11-009797.paper |
| 2008-12-30 | ARS | 2008-06-30 | AUTO-GENERATED PAPER DOCUMENT | 9999999997-09-001140.paper |
| 2008-06-03 | ARS | 2007-06-30 | AUTO-GENERATED PAPER DOCUMENT | 9999999997-08-027200.paper |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |